Posts

Best Pharma Consulting Company

Image
  Description BLINCYTO (blinatumomab) is a CD19-directed bispecific CD3 T cell adaptor that can bind to CD19 (expressed on cells of B lineage origin) and CD3 (expressed on T cells). BLINCYTO is produced in Chinese hamster ovary cells. It is composed of 504 amino acids and has a molecular weight of approximately 54 kilodaltons. Each package of BLINCYTO contains 1 vial of BLINCYTO and 1 vial of IV solution stabilizer. BLINCYTO is provided in a single-dose vial as a sterile, preservative-free white to off-white lyophilized powder for intravenous administration. Each BLINCYTO single-dose vial contains 35 mcg of blinatumomab, citric acid monohydrate (3.35 mg), lysine hydrochloride (23.23 mg), polysorbate 80 (0.64 mg), trehalose dihydrate (95.5 mg) and hydrogen Sodium oxide adjusts the pH to 7.0. After reconstitution with 3 mL of preservative-free sterile water for injection (USP), the resulting concentration is 12.5 mcg/mL blinatumomab. The IV solution stabilizer is provided in a single...
Post a Comment
Read more

Best Pharma Consulting Company

Image
 Drug Name Atriance 5 mg/ml infusion solution 2. Qualitative and quantitative composition Each milliliter of solution contains 5 mg of Nelarabine. Each vial contains 250 mg of Nelarabine. Excipients with known effects Each milliliter of solution contains 1.770 mg (77 micromoles) of sodium. For a complete list of excipients, see section 6.1. 3. Drug form Infusion solution. Clear colorless solution. 4. Clinical details 4.1 Treatment indications Nelarabine is suitable for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) who have not responded or relapsed after treatment with at least two chemotherapy regimens. Because the number of patients in these conditions is small, the information supporting these indications is based on limited data. 4.2 Modes and methods of administration Nelarabine can only be administered under the guidance of a doctor who has experience in the use of cytotoxic agents. Ontology The complete b...
Post a Comment
Read more

Best Pharma Consulting Company

Image
  What is Arzerra? how to use? Arzerra (ofatumumab) injection is a monoclonal antibody used to treat chronic lymphocytic leukemia. Arzerra is usually given after other drugs have been tried but the symptoms have not been successfully treated. What are the side effects of Arzerra? Common side effects of Arzerra include: nausea, Vomiting diarrhea, tired Swelling of hands/ankles/feet, Difficulty sleeping, Skin rash, or Cold symptoms such as stuffy nose, sneezing and sore throat. Arzerra reduces bone marrow function, which may result in a decrease in the number of blood cells, such as red blood cells, white blood cells and platelets. This side effect of Arzerra can cause anemia, reduce the body's ability to fight infection or cause easy bruising or bleeding. Tell the doctor if you have the following symptoms: Easy bruising/bleeding, Pale skin, Unusual tiredness, or Signs of infection (eg fever, chills, cough, persistent sore throat). caveat Activation of hepatitis B virus and progressi...
Post a Comment
Read more

Best Pharma Consulting Company

Image
  What is Adcetris and how to use it? Adcetris is a prescription medicine used to treat symptoms. Adcetris can be used alone or together with other drugs. Adcetris belongs to a class of drugs, called anti-tumor drugs, anti-microtubules; anti-Nectin-4 monoclonal antibodies; anti-tumor drugs, anti-CD30 monoclonal antibodies. It is not clear whether Adcetris is safe and effective in children. What are the possible side effects of Adcetris? Adcetris can cause serious side effects, including: measles, Difficulty breathing, Swelling of your face, lips, tongue or throat, fever, sore throat, Burn in your eyes Skin pain The red or purple rash spreads and causes blistering and peeling, dizziness, nausea, Chills Itching, Difficulties in speech, thought, vision or muscle movement, numbness, weakness, Burning pain Numbness Loss of sensation in the arms or legs, Sudden chest pain or pressure, respite dry cough, Shortness of breath, Pain or burning when urinating, thirst, Increased urination, Dry...
Post a Comment
Read more

Best Pharma Consulting Company

Image
  Formulations and advantages pill 15 mg 45 mg Chronic myeloid leukemia Suitable for patients in the chronic phase (CP) of chronic myeloid leukemia (CML) who are resistant or intolerant to at least 2 previous kinase inhibitors It is also suitable for accelerated phase (AP) or explosion phase (BP) CML without indication of other kinase inhibitors, and T315I positive CML (CP, AP, BP) CP-CML Initial 45 mg PO qDay When reaching ≤1% BCR-ABL1IS, reduce q to 15 mg PO daily Patients who fail to respond will re-raise the dose to the previously tolerated 30 mg or 45 mg PO qDay dose Continue until the dose is raised again, the reaction disappears or unacceptable toxicity occurs AP-CML or BP-CML The optimal dose has not been determined 45 mg PO qday AP CML Consider reducing the dose of AP CML in patients who have already achieved a major cytogenetic response Continue treatment until loss of response or unacceptable toxicity If there is no response after 3 months, please consider discontinuing ...
Post a Comment
Read more

Best Pharma Consulting Company

Image
  Description SYNRIBO contains the active ingredient omexetine mesylate succinate, a type of ceftazidoxime. It is a protein synthesis inhibitor. Omascitabine syringate is prepared through a semi-synthetic process of ceftazidine, which is an extract of the leaves of the genus Ceftazid. The chemical name of omestatin mesylate succinate is ceftacine, 4-methyl butyrate (2R)-hydroxy-2-(4-hydroxy-4-methylpentyl). Oxcarbetine mesylate succinate has the following chemical structure: SYNRIBO® (Omexitine mesylate succinate) structure diagram The molecular formula is C29H39NO9 and the molecular weight is 545.6 g/mol. SYNRIBO for injection is a single-use sterile, preservative-free, white to off-white freeze-dried powder. Each vial contains 3.5 mg omecetine mesylate succinate and mannitol. SYNRIBO is intended to be reconstituted with 1.0 mL of 0.9% Sodium Chloride Injection (USP) for subcutaneous administration. The pH of the reconstituted solution is between 5.5 and 7.0. Indications and dosag...
Post a Comment
Read more

Best Pharma Consulting Company

Image
  Indications Instruct VENCLEXTA: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Combine with azacitidine, decitabine or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML): 75 years or older, or Patients with comorbidities cannot use intensive induction chemotherapy. Important safety information Contraindications In patients with CLL/SLL, simultaneous use of VENCLEXTA with strong CYP3A inhibitors is contraindicated because it may increase the risk of tumor lysis syndrome (TLS). Tumor lysis syndrome Patients treated with VENCLEXTA developed tumor lysis syndromes, including fatal events and renal failure requiring dialysis. VENCLEXTA can cause rapid tumor reduction, so in all CLL/SLL patients, there is a risk of TLS during the start and the start phase, and during the restart period after the dose is interrupted. Changes in blood chemistry consistent with TLS need to be dealt wi...
Post a Comment
Read more